nflammatory activation is inherently related to the development and clinical course of coronary artery disease, 1,2 and regarding non-specific inflammatory indices, baseline leukocytosis has been previously related to increased mortality in unselected cases of ST-elevation myocardial infarction (STEMI) treated with either primary percutaneous coronary intervention (PCI) or thrombolysis. [3] [4] [5] From among the differential components neutrophils (Ns), lymphocytes (Ls) and the N to L ratio have been also associated with clinical outcomes in STEMI patients. [6] [7] [8] [9] [10] With respect to C-reactive protein (CRP), thrombolytic studies show conflicting results [11] [12] [13] and the data regarding patients treated with primary PCI are limited and do not examine early results in cases of STEMI. [14] [15] [16] [17] Recently, the impact of inflammatory activation on direct worsening of acute clinical outcome in acute coronary syndromes (ACS) has been opposed to stable conditions in coronary disease, highlighting distinct pathomechanisms for both conditions. 1,2 Therefore, the longer term follow-up studies associate inflammatory indices with clinical outcome Circulation Journal Vol.72, February 2008 of STEMI, the more events may be attributed to atherosclerosis progression, leading to dilution and misinterpretation of the true significance of inflammation in the acute phase of STEMI. Moreover, in the advent of conceivable anti-CRP therapy in STEMI, precise determination of its role in humans becomes increasingly important. 18 Therefore, in the present study we investigated the relationship of non-specific inflammatory activation and the immediate outcome of STEMI treated with primary angioplasty.
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Methods

Study Population
Our study group consisted of 1,078 unselected prospective registry patients enrolled during 2.4 years following April 2002 (with exclusion of 120 patients admitted during a hospital laboratory refurbishment period when routine assay of high-sensitivity CRP (hs-CRP) was not performed off-hours). A predefined set of data for consecutive, unselected patients with STEMI and time from pain onset to admission up to 12 h who are admitted for primary angioplasty have been recorded in a prospective hospital registry since February 2001. 3 STEMI is defined as ST-elevation of ≥0.1 mV in >1 limb leads or ≥0.2 mV in contiguous chest leads or left bundle branch block on presentation.
Per institutional requirements, since April 2002 all the patients on admission and prior to any coronary procedures routinely have blood drawn for hs-CRP as well as for differential and white blood cell (WBC) count. In all patients blood is drawn for the analyses just after sheath insertion and prior to any coronary procedures. Pre-and postprocedural angiograms are analyzed by 2 operators and the assessment of pre-and post-procedural Thrombolysis In Myocardial Infarction (TIMI) flow grade in the infarct-related artery, and the number of diseased vessels is determined by consensus. Clinical and angiographic data, including sex, age, Killip class >1, known diabetes mellitus, hypertension, hypercholesterolemia, family history of coronary disease, previous myocardial infarction, current smoking, time from onset to admission, culprit artery TIMI flow less than 2 prior to and after (further referred as "final TIMI flow <2") coronary intervention, presence of multivessel disease (MVD), coronary stenting, glycoprotein IIb/IIIa use, are prospectively determined at the time of the primary procedure, as are systolic blood pressure and heart rate. Either creatine kinase (CK) or myocardial band CK (CK-MB) is routinely assessed in all patients on admission and on at least 1 consecutive day in surviving patients. In all the study patients, primary angioplasty of the culprit lesion was attempted in accordance with the standard techniques, following a loading dose of aspirin (300-500 mg) and clopidogrel (300 mg). Abciximab administration was at the discretion of the physician performing the procedure; however, it is encouraged in case of either diabetes or anterior location of the infarction.
Measurement of WBC and Differential Counts, and Level of hs-CRP
The WBC count and its subtypes were obtained using an automated differential leukocyte counter (Sysmex K-4500; TOA Medical Electronics, Kobe, Japan), which uses a direct current method, ensuring accurate and stable hematology testing. Plasma concentrations of CRP were measured by fully automated latex-enhanced immunoturbidimetric assays on a Cobas Integra 800 (Roche Diagnostics, Mannheim, Germany). The CRP assay has an analytical sensitivity of 0.085 mg/L and a measuring range up to 160 mg/L in undiluted samples. Its imprecision range is 1.5-2.9% CV. The upper limit of the reference range in healthy adults is 5 mg/L.
Study Endpoints
In-hospital mortality was regarded as the main study outcome. The mortality data were obtained for all subjects based on hospital records.
The infarct size, defined as the peak CK or CK-MB up to 72 h following infarction multiplied by the upper limit normal (ULN), comprised the secondary endpoint.
The study protocol was approved by the local ethics committee.
Statistical Analysis
The baseline inflammatory parameters were analyzed as continuous data. In case the continuous data distribution was not normal the data were log-transformed and are presented as median values (25 th from symptom onset to hospital admission would affect the levels of leukocytes and hs-CRP, the time was forced into the multivariate model irrespective of the results of univariate analysis. Hosmer-Lemeshow goodness-of-fit analysis was performed to assess the expected vs the observed outcomes in the multivariate model. The Hosmer-Lemeshow goodness-of-fit statistic was obtained by calculating the Pearson chi-square test from the 2×g table of the observed and expected frequencies. The greater the p value (smaller the chi-square number), the better the model fits the data. For infarct size, multivariate linear regression was used. Risk ratios and p values are reported with regression models that adjust for the factors that were independently associated with the outcome variable. The relationship of infarct size and the inflammatory parameters is presented graphically using Pearson's correlation. Significance is assumed at the 2-tailed p-value <0.05. For exploratory purposes, a correlation of the WBC count and hs-CRP with other baseline and procedural data was performed (Pearson's or Spearman's correlations as appropriate); because of the high number of analyses, to avoid spurious associations significant correlations were assumed at the 2-tailed p-value <0.01. Data analysis was performed using SPSS version 9.0 (Chicago, IL, USA).
Results
Baseline Characteristics
The study population consisted of 1,078 patients. Nonsurvivors on admission were older, less frequently smokers, had higher heart rate and lower blood pressure, and more often had acute heart failure. On catheterization they more often had MVD, baseline and final TIMI <2 flow in the culprit artery (Table 1) .
Total and differential subtype WBC counts and hs-CRP levels were not normally distributed. Baseline values are presented as quartiles in Table 2 .
A higher WBC count was significantly correlated with younger age, lower systolic blood pressure, less previous episodes of angina, higher Killip class, and worse baseline TIMI flow in the culprit artery, whereas hs-CRP was significantly correlated to longer time to admission, presence of hypertension, and worse final TIMI flow in the culprit artery. Importantly, all these correlations were very weak (R 2 <0.1).
For both younger patients (<65 years) and the elderly (≥65 years) in-hospital mortality was lower in those with a WBC count below median as compared to patients with a high WBC count (respectively, 0.6% vs 4.3% for patients in the lower age category and 7.7% vs 13.5% in the elderly, p<0.001 for both).
Univariate Prediction of In-Hospital Death
A total of 68 (6.3%) patients died during the index hospitalization (Table 1) . According to univariate analysis, an increased hazard ratio (HR) of death was associated with older age (HR 1.06 per year; p<0.001), non-smoking (HR 2.61; p=0.004), Killip class >1 (HR 12.20; p<0.001), heart rate (HR 1.02 per beat; p<0.001), systolic blood pressure (HR 0.98; p<0.001), MVD (HR 3.63; p<0.001), pre-procedure TIMI flow >2 (HR 0.18; p=0.018), postprocedure TIMI flow >2 (HR 0.23; p<0.001), previous myocardial infarc- tion (HR 2.11; p=0.023), WBC (after log transformation) (HR 3.16; p=0.004), N (HR 2.34; p=0.020), and hs-CRP (HR 1.47; p<0.001). No significant relationship was found between the main outcome and the N/L ratio (p=0.081) or L count (p=0.907). The relationship between hs-CRP or WBC count and mortality is presented in Fig 1 .
Results of Multivariate Analyses
In addition to the univariate predictors of outcome, time from symptom onset to hospital admission (HR 1.05; p= 0.326) was forced into the multivariate regression analysis and according to those results the independent clinical variables predictive of in-hospital death (further referred to as "core variables") included older age (HR 1.05 per year; p= 0.001), Killip class >1 (HR 6.89; p<0.001), heart rate (1.02 per beat; p=0.005), systolic blood pressure (HR 0.99 per mmHg; p=0.012), MVD (HR 2.46; p=0.034), and postprocedure TIMI flow >2 (HR 0.36; p=0.014). The HosmerLemeshow statistic for the mutivariate model was not significant, indicating little departure from a perfect fit (chisquare 5.81, p=0.668). After separate addition of the inflammatory parameters (log transformed) to the model, only WBC (HR 6.26; p=0.001) and hs-CRP (HR 1.38; p=0.009) proved to be independent predictors of outcome; the N count was not. After both WBC count and hs-CRP were entered into the multivariate model together, both retained their independent association with the main study outcome (HR 5.73; p=0.002 and HR 1.36; p=0.012 respectively).
Secondary Outcomes
The mean infarct size peaked at the level of 19.2±19.5× ULN and Fig 2 shows the correlation between inflammatory parameters and infarct size. According to the univariate linear regression analysis, increased infarct size was related to the following inflammation-related parameters: WBC (p< 0.001) and N counts (p<0.001), and the N/L ratio (p<0.001). Other variables included lack of hypertension (p=0.002), abciximab use (p<0.001), higher heart rate (p<0.001), and baseline TIMI flow <2 (p<0.001). The hs-CRP level was not related to infarct size. In separate multivariate analyses all the leukocyte-related parameters retained their independent relationships with infarct size. However, when the independent inflammatory parameters were entered into a single model, only WBC (p<0.001) count retained its independent association with infarct size.
Discussion
Summary of Study Findings
A unique contribution of our study is the assessment of the relative significance of association of various non-specific inflammatory measures with acute outcomes in unselected STEMI patients treated with primary PCI. Our data indicate a special role for both CRP and the WBC count, which were found to be associated with early mortality independently of each other. Neither of the differential components retained an independent predictive value in the presence of other baseline clinical covariates.
Intersection: Inflammation, Infarction, Intervention
Links between increased inflammatory activation, ACS and PCI are complex, although basically inflammation is inherently causally linked to the initiation and progression of atherosclerosis and to an increased incidence of atherothrombotic events. 1 However, there is strong evidence that the significance, mechanisms and consequences related to inflammation differ between stable and acute conditions, and in the latter excessive inflammatory response may directly contribute to worse outcome. 2, 18 Therefore, our study focused on exploring the relationship of inflammatory activation with the immediate outcome of STEMI treated with primary angioplasty, which is an important feature distinguishing our study from most other clinical studies covering the topic. Moreover, increased inflammation is a phenomenon encompassing a broad range of pathophysiologic mechanisms and both leukocytosis and increased hs-CRP level are commonly used as its synonyms, but usually examined in separate analyses. As shown in our analysis, however, both markers of inflammation seem to be related to different baseline variables and to differing outcomes, suggesting different pathophysiologic pathways and in consequence various clinical implications.
Increased inflammatory status in STEMI patients may be linked to more extensive atheroma 1, 19 and overall worse patient condition on admission. 3 Moreover, excessive inflammatory activation may indicate susceptibility to development of systemic inflammatory response syndrome contributing to adverse outcome in critically ill patients. 2 In the present study in accordance with previous reports, the hs-CRP level tended to be related to MVD. Also, a higher Killip class on admission was significantly correlated to the WBC count and tended to be related to the hs-CRP value. Interestingly, younger patients with STEMI had higher Leukocytosis, which could be subscribed to higher incidence of smoking than in older patients. Importantly, the relationship of leukocytosis with in-hospital death was consistent in both age categories (ie, <65 years and >65 years); however, in younger patients higher inflammation was associated with a 7-fold increase in mortality, whereas in the elderly it was only 2-fold.
PCI itself is a strong additional inflammatory stimulus and may cause acute local and systemic inflammatory responses that are predictive of post PCI complications. 20, 21 Plausibly, interference of the baseline and additional inflammatory response inflicted by coronary stenting in STEMI may account for some procedural pitfalls both at the macroas well as the microvascular level. Indeed in our study a higher hs-CRP level correlated with worse final TIMI flow in the infarct-related artery. This issue of whether there is a direct causal relationship between non-specific inflammatory markers, such as hs-CRP or leukocytes, and the clinical course of ACS remains largely unresolved. Some experimental data suggest that CRP may be involved in myocardial tissue damage in myocardial infarction and its inhibition has been recently shown to limit infarct size in rats. 19, 22 Leukocytosis may be related to infarction outcome through multiple mechanisms, including proteolytic and oxidative damage to the endothelial cells, plugging of the microvasculature, inducement of hypercoagulability, and infarct expansion. 23 These are likely explanations of the correlation between the baseline WBC or N count and the infarct size as measured by peak CK/CK-MB release. Similar associations have been observed in other studies, including a recent report of Mariani et al who showed a significant relationship of the N and M counts with signs of effective myocardial reperfusion in STEMI patients treated with primary angioplasty. 9, 24, 25 
Clinical Outcomes
According to data from multicenter registries, in-hospital mortality for STEMI patients treated with primary angioplasty ranges from 5% to 8%, 26, 27 which is similar to the event rate of our cohort. Earlier reports suggested that in patients presenting with ACS, coronary intervention might alleviate the relationship between inflammatory parameters and clinical outcome. Analysis of the PURSUIT trial data reveals that in patients with non-ST-elevation ACS, leukocytosis did not correlate with the clinical outcomes of patients undergoing coronary intervention as opposed to medically treated subjects. 28 Similarly, for STEMI patients treated with mechanical reperfusion, the myocardial salvage index may not differ between high vs low hs-CRP groups, whereas in thrombolysed patients the salvage index may inversely correlate with the levels of hs-CRP. 29 Based on these data it may be concluded that the relationship between inflammatory activation and clinical outcome in ACS likely differs in patients treated with mechanical intervention as compared with medical treatment. This fact urges us to establish the relationship between baseline inflammatory activation and outcome in STEMI patients treated solely with mechanical reperfusion.
Relationship of Baseline hs-CRP Level and Early Mortality
Our data suggest an independent relationship of the baseline CRP level and early mortality in unselected STEMI patients treated with mechanical reperfusion. The relationship remained significant after correction for baseline leukocytosis, another strong inflammatory correlate of mortality in STEMI patients. 3 Our data also differ from those of other studies with respect to the relatively large number of patients studied, which enabled us to assess early definite outcomes of STEMI. Earlier reports have provided conflicting evidence on the associations of baseline CRP and mortality in STEMI patients treated with thrombolysis. Nikfardjam et al found that the increased risk of death observed in patients with high CRP was attributable to other baseline variables, 30 and another study's results suggest that CRP is not predictive of adverse events shortly after infarction, 31 contrary to our findings. However, Suleiman et al found that CRP assessed within 12-24 h post infarction onset was an independent predictor of 30-day mortality. 12 Likewise, Foussas et al showed a correlation between baseline CRP and 30-day mortality in thrombolysed patients. 13 With reference to patients treated with primary angioplasty, a study by Hon-Kan et al showed a relationship between the pre-PCI CRP level and 30-day combined endpoint, including death, recurrent ischemia, or re-occlusion of the infarct-related artery, assessed in 146 patients. 32 There are 2 previous reports regarding the association of CRP and mortality in STEMI patients treated with primary angioplasty. Hoffman et al showed a relationship between high CRP and 1-year death in 191 STEMI patients; however, the reported mortality rate (25.6%) significantly differs from that of our cohort and also of other studies. 14 Moreover, despite the reported trend in association of CRP and cardiogenic shock, and despite hemodynamic status being established as 1 of the strongest outcome determinants in STEMI, neither uni-nor multivariate analyses provided correction for either Killip class or cardiogenic shock. Those facts may limit the applicability of the cited results to the broader STEMI population. The results of a post-hoc analysis derived from the COMMA trial show a correlation between baseline CRP and 90-day mortality in 337 patients; 15 however, as admitted by the authors of that report, their findings are hypothesis-generating rather than establishing a relationship, not only because of intrinsic differences between unselected vs clinical trial patients, 16, 17 but also because of multiple additional factors accounted for in the study's limitations, including study entry criteria or the prespecified proportion of patients with inferior infarction. 33 Another additional value of our study in reference to the 2 latest reports is a relatively high number of patients, which enabled us to analyze the early hard endpoints of STEMI, without the intervening "atherosclerosis progression" events.
Leukocytosis
Current data are consistent with our previous findings on the significant relationship between leukocytosis and mortality in unselected STEMI patients treated solely with mechanical reperfusion. 3 Unlike our study, the Stent PAMI trial data reveal no significant relationship between baseline leukocytosis and mortality in STEMI patients treated with primary PCI. 25 Other reports refer to data combining STEMI and non-STEMI patients or mechanical and medical treatment of ACS. The GRACE registry encompassing unselected ACS patients, including those with STEMI, of whom one-third was treated with coronary intervention, reveals a significant relationship between baseline leukocytosis and in-hospital mortality. 4 The combined results of the COMMA and COMPLY trials show a correlation between baseline WBC count and 90-day mortality in STEMI patients treated with PCI or thrombolysis; however, the level of significance reported is relatively low, especially given the lack of a multivariate analysis. 24 
Differential WBC Count
Our data reveal a significant relationship between the N count and mortality in STEMI patients treated with primary PCI; however, the relationship is not maintained after correction for other clinical correlates. Neither the L count nor N to L ratio correlated with in-hospital mortality in our patients. N, L and especially the N to L ratio have been previously associated with clinical outcomes in coronary disease, including STEMI patients. 6 In STEMI patients treated with primary angioplasty a higher N count has been previously correlated with indices of increased infarct size, worse myocardial reperfusion or worse ventricular function, but not with mortality. [7] [8] [9] [10] Our data also do not rule out a relationship between N count and mortality, but rather suggest that the correlation is less significant than that of the WBC count and probably too weak to be apparent in a cohort of our size.
Study Limitations
This study was prospective in patient and data collection, but was observational in nature and subject to limitations including possible uncorrected confounding. The study entails a population in which coronary angioplasty was performed, and results might differ for STEMI patients treated by other means, who were untreated or those who died prior to hospital admission. Our data do not support a pathological explanation or suggest any causative relationship between inflammatory parameters and clinical outcome. Replication of these results in other populations is encouraged.
Conclusions and Implications
In a prospective cohort of STEMI patients treated according to contemporary recommendations, hs-CRP and WBC count were found to be associated with early mortality independently of each other. Our data strengthen the links between CRP or WBC count and early outcomes of STEMI in humans and suggest different pathological significance of the 2 non-specific inflammatory markers in STEMI. Proof of concept studies should provide the ultimate answer regarding the causality of the association. Further studies are warranted.
